Tag: Yahoo Finance

Banks Are Impossible for Anyone to Understand

(Bloomberg Opinion) -- A simple lesson we should have learned from the financial crisis is that complexity begets abuse, and undermines stability. Yet the key measure we use to determine banks’ health is so fiendishly difficult to understand that outsiders have no choice but to accept what we’re told by the lender.That’s the conclusion of a broad U.K. government review of the audit industry unveiled this week. Donald Brydon, the former chairman of London Stock Exchange Plc who ran the review, considered whether accountants should be brought in to verify how banks calculate the all important “risk-weighted asset” measure. Alarmingly, he concluded that there was no point because even trained auditors would struggle to get their heads around these calculations, unless banks employed an army of them. If that’s true, then what hope for ordinary shareholders or bank supervisors?After all, we’re talking here about the figure that lenders and their regulators use to assess how much...

Water around Rio Tinto's Madagascar mine is high in lead, uranium – study

Water downstream of a Rio Tinto mine in southern Madagascar contains high concentrations of uranium and lead, potentially endangering local residents who depend on a nearby lake and river for drinking water, a study released on Friday found. Lead, when ingested, can impede the mental and physical development of children, while uranium can cause kidney damage. The study commissioned by southern Madagascar-focused British environmental charity The Andrew Lees Trust found that concentrations of uranium were 350 times higher downstream of the QIT-Madagascar Minerals (QMM) mine than upstream of it, and that lead concentrations were 9.8 times higher....

Novartis wins Medicaid approval for new sickle cell drug in key U.S. states

The approvals from the Florida and Alabama Medicaid health programs for the poor and disabled mark exceptionally fast acceptance for the treatment, which can cost up to $113,000 annually for an individual patient, excluding discounts, said Ameet Mallik, who heads the Swiss drugmaker's oncology division. In November, the U.S. Food and Drug Administration approved Adakveo and Global Blood Therapeutic Inc's Oxbryta, which carries a list price of $125,000 per year....